Stockholders' Equity (Tables)

12 Months Ended

Dec. 29, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Grants and Exercises Under the Company's Option Plans

During the years ended December 29, 2024, December 31, 2023, and December 25, 2022, the following values relate to the exercises under the Company’s option plans:

	2024		2023		2022
Total intrinsic value of options exercised (in thousands)	$	—	$	80.8	$	163.0

Schedule of Restricted Stock Units Activity

The following table summarizes the Company’s Restricted Stock Unit activity:

	Restricted Stock Units (000’s)	Weighted-Average Grant Date Fair Value
Nonvested balance at December 31, 2023	4,935	$	12.72
Granted	1,509	$	19.00
Vested	(2,398)	$	18.48
Forfeited or expired	(38)	$	16.10
Vested but not released	(220)	$	14.11
Nonvested balance at December 29, 2024	3,788	$	11.45

Schedule of Assumptions and Resulting Fair Values of Options Granted

The assumptions and resulting fair values of options granted for 2024, 2023 and 2022 were as follows:

	Offering Periods January 1 to December 31 2024	Offering Periods January 1 to December 31 2023	Offering Periods January 1 to December 31 2022
Expected term (in years)(1)	0.5	0.5	0.5
Risk-free interest rate(2)	5.26% - 5.33%	4.76% - 5.47%	0.19% - 2.51%
Expected volatility(3)	40.15% - 40.68%	41.65% - 45.77%	40.52% - 60.79%
Expected dividend yield(4)	—%	—%	—%
Weighted average grant-date fair value per share	$5.40	$3.30	$4.80

(1) The expected term is equivalent to the offering period.

(2) The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant with a term equal to the expected term.

(3) The Company estimated implied volatility based upon trailing volatility.

(4) The Company has no history or expectation of paying dividends on its common stock.